Breast最新文献

{"title":"Patient perception on risk of recurrence and decision-making in the management of HER2-positive early breast cancer: Insights from the ASKHER2 European survey","authors":"Matteo Lambertini ,&nbsp;Christian Jackisch ,&nbsp;Olivier Trédan ,&nbsp;Maria Vidal ,&nbsp;Mário Fontes-Sousa ,&nbsp;Antonios Valachis ,&nbsp;Rosanna D'Antona ,&nbsp;Marcelo Ruz ,&nbsp;Eugenia Krone ,&nbsp;Miriam Brice ,&nbsp;Erwan Berjonneau ,&nbsp;Soraia Matos ,&nbsp;Olivia Dialla ,&nbsp;Laure Guéroult-Accolas","doi":"10.1016/j.breast.2025.104456","DOIUrl":"10.1016/j.breast.2025.104456","url":null,"abstract":"<div><h3>Background</h3><div>Perceived risk and fear of recurrence in patients with breast cancer (BC) is a matter of concern and may affect their health behaviours and their ability to participate in decision making during their treatment. This survey aimed to examine perceptions and concerns of patients with HER2+ BC.</div></div><div><h3>Materials and methods</h3><div>A multi-country, non-interventional, direct-to-patient online survey was conducted between July 22, 2022 and March 1, 2023 in six European countries using a multi-modal recruitment approach.</div></div><div><h3>Results</h3><div>Out of 622 included patients, 96.8 % desired involvement in treatment decisions, and 58.5 % felt they had significant influence in the decision-making process. A total of 20.9 % of patients were unaware of their personal risk of recurrence, and 19.5 % reported not discussing this risk with their healthcare providers. The fear of disease recurrence, death, and treatment failure were identified as the most important concerns. Moreover, 30.4 % perceived they had clear communication with healthcare providers on risk of recurrence. A total of 64.5 % were willing to take extra treatments, 60.2 % to undergo more surgery to reduce recurrence risk and 68.5 % were willing to accept further treatments even if recurrence risk decreased by less than 50 %.</div></div><div><h3>Conclusion</h3><div>Results of this multinational direct-to-patient study examining the perceptions and concerns of women with HER2+ breast cancer underscore the need for physicians to proactively involve patients in their decision-making process, enabling them to participate in a patient-centred approach during treatment decisions.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104456"},"PeriodicalIF":5.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy","authors":"Charles E. Geyer Jr. ,&nbsp;Sibylle Loibl","doi":"10.1016/j.breast.2025.104450","DOIUrl":"10.1016/j.breast.2025.104450","url":null,"abstract":"<div><div>Reductions in HER2-protein IHC intensity and <em>HER2</em>-gene amplification in residual invasive breast cancer following neoadjuvant therapy for HER2-positive breast cancer have been described and are associated with worse outcomes. T-DM1 requires initial binding to HER2 for activity, so concerns have been raised regarding T-DM1 activity when changes are sufficient to classify residual disease as HER2-negative. The KATHERINE trial assessed HER2 status of residual disease from 845 patients with HER2-positive status on pretherapy biopsies, of which 70 were negative on retesting. With 8 years of median follow-up, 7-year IDFS was 60.3 % with trastuzumab compared to 95.2 % with T-DM1, consistent with clinically meaningful benefit from T-DM1 in these 70 patients.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104450"},"PeriodicalIF":5.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CADONOT: Comparing axillary dissection or not in breast cancer surgery","authors":"André Mattar ,&nbsp;Marcelo Antonini ,&nbsp;Francisco Pimentel Cavalcante ,&nbsp;Felipe Zerwes ,&nbsp;Eduardo de Camargo Millen ,&nbsp;Fabricio Palermo Brenelli ,&nbsp;Antônio Luiz Frasson ,&nbsp;Patrícia Carvalho Baruel ,&nbsp;Lucas Miyake Okumura ,&nbsp;Leonardo Ribeiro Soares ,&nbsp;Marcelo Madeira ,&nbsp;Marina Diógenes Teixeira ,&nbsp;Andressa Gonçalves Amorim ,&nbsp;Larissa Chrispim de Oliveira ,&nbsp;Marcellus do Nascimento Moreira Ramos ,&nbsp;Gil Facina ,&nbsp;Ruffo de Freitas Junior ,&nbsp;Henrique Lima Couto ,&nbsp;Sabrina Monteiro Rondelo ,&nbsp;Renata Montarroyos Leite ,&nbsp;Juliana Monte Real","doi":"10.1016/j.breast.2025.104453","DOIUrl":"10.1016/j.breast.2025.104453","url":null,"abstract":"<div><h3>Introduction</h3><div>Sentinel lymph node biopsy (SLNB) is the gold standard for the axillary evaluation of clinically node-negative early breast cancer. The ACOSOG Z0011 study demonstrated the safety of omitting axillary dissection for limited SLNB disease, with other trials confirming SLNB alone or with axillary radiotherapy (AR) as non-inferior.</div></div><div><h3>Methods</h3><div>We followed PRISMA guidelines and registered at PROSPERO. Using Medline, Embase, and Cochrane, we reviewed randomized controlled trials (2010–2024). Outcomes, including 5-, 8-, and 10-year OS, DFS, recurrence rates, and lymphedema, were analyzed with R software and assessed for bias (Cochrane RoB) and evidence quality (GRADE). The focus was ALND vs. SLNB, alone or with AR, in cT1-T3 BC with 1–2 metastatic SLNs.</div></div><div><h3>Results</h3><div>Thirteen articles from seven randomized controlled trials (RCTs) were included, covering 7338 women with a follow-up period of 2.8–10 years. SLNB was associated with a 65 % lower risk of lymphedema than ALND, with no significant differences in the 5-, 8-, or 10-year OS, DFS, or recurrence rates. A meta-analysis comparing micrometastasis and macrometastasis showed no impact on outcomes, indicating that ALND may be unnecessary in either case. Recurrence rates also did not differ between SLNB and ALND, reinforcing SLNB's significantly lower lymphedema risk of SLNB.</div></div><div><h3>Conclusions</h3><div>This systematic review and meta-analysis support SLNB as a safe and effective alternative to ALND in early-stage BC with 1–2 positive SLNs, providing comparable survival and recurrence outcomes, with fewer complications.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104453"},"PeriodicalIF":5.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143820468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic factors and treatment insights for metastatic malignant phyllode tumors","authors":"Mengjia Han ,&nbsp;Yunyi Zhang ,&nbsp;Rong Lei ,&nbsp;Zijia Lai ,&nbsp;Zilin Zhuang ,&nbsp;Yulu Zhang ,&nbsp;Xun Li ,&nbsp;Xiaojun Li ,&nbsp;Rurong Jia ,&nbsp;Qiongchao Jiang ,&nbsp;Feng Ye ,&nbsp;Yan Nie","doi":"10.1016/j.breast.2025.104455","DOIUrl":"10.1016/j.breast.2025.104455","url":null,"abstract":"<div><h3>Background</h3><div>The aim of this study is to contribute a better understanding of metastatic malignant phyllode tumors (MMPTs) by exploring its prognostic factors, describing treatment landscape, and providing optimal treatment choices.</div></div><div><h3>Methods</h3><div>This retrospective multicentric study was included 43 patients with MMPTs who received treatment from 2009 to 2023 in four centers. The primary endpoint of the study was overall survival (OS).</div></div><div><h3>Results</h3><div>The median overall survival of these patients was 7.27 months (range: 0.63–118.53) and the median follow-up time was 16.8 months (range: 2–188). The median age of these patients were 49 years. The median metastasis-free survival (MFS, it is the time between initial diagnosis and diagnosis of metastatic disease) was 7.27 months, and the most common site of metastasis was lung (35/43, 81.4 %). Treatment for MMPTs primarily consisted of systemic chemotherapy and metastasectomy.</div><div>Multivariate analysis revealed that chemotherapy after metastasis (HR = 0.250, 95 % CI 0.109–0.571; <em>P</em> = 0.001) and MFS &gt;6 months (HR = 0.407, 95 % CI 0.198–0.836; P = 0.014) were independently associated with OS. The most common chemotherapy regimen was anthracyclines along with ifosfamide (AI), with the median progression-free survival of 5.5 months. Metastasectomy did not significantly improve OS.</div></div><div><h3>Conclusion</h3><div>The study findings highlight the significance of systemic treatment (chemotherapy) and the impact of MFS on prognosis of MMPTs. For these patients, systemic treatment may improve survival outcomes. And patients with MFS &lt;6 months appear to have a poorer prognosis.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104455"},"PeriodicalIF":5.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of surgical timing post-neoadjuvant chemotherapy on survival outcomes in breast cancer patients: A comprehensive systematic review and meta-analysis","authors":"Dandan Wang ,&nbsp;Xiaowei Sun ,&nbsp;Wen Sun ,&nbsp;Ruoxi Wang,&nbsp;Hong Pan,&nbsp;Wenbin Zhou","doi":"10.1016/j.breast.2025.104454","DOIUrl":"10.1016/j.breast.2025.104454","url":null,"abstract":"<div><h3>Background</h3><div>Increasing evidence supports the use of neoadjuvant chemotherapy (NAC) prior to surgery for breast cancer. However, the optimal timing between NAC and surgery had yet to be fully elucidated. This meta-analysis aims to assess how the optimal interval time (OTT) between NAC and surgery affects outcomes in breast cancer, providing additional evidence for clinical practice and future research.</div></div><div><h3>Methods</h3><div>PubMed<strong>,</strong> Web of Science and Cochrane Library databases in English were systematically searched for this systematic review. All included studies investigated the variations in surgical timing following NAC and their effects on breast cancer outcomes. The endpoints included the rate of pathological complete response (pCR), overall survival (OS), recurrence free survival (RFS), and disease-free survival (DFS). This study has been registered with PROSPERQ.</div></div><div><h3>Results</h3><div>Eleven eligible studies were identified, encompassing a total of 10,834 cases, all of which received surgery post-NAC. All studies were retrospective in nature. Ultimately, compared to intervals within 4 weeks, patients who underwent surgery&gt;8weeks post-NAC demonstrated a statistically significant worse OS (HR = 1.21, 95 % <em>CI</em>: 1.06–1.40, <em>p</em> = 0.333 for heterogeneity). No significant difference of OS was observed between patients with OTT of 4–8 weeks vs &lt; 4 weeks. Notably, patients with an OTT of 4–8 weeks (HR = 1.18, 95 % <em>CI</em>: 1.10–1.26, <em>I</em>^<em>2</em> = 0.0 %, p = 0.931 for heterogeneity) and&gt;8weeks (HR = 1.21, 95 % <em>CI</em>: 1.13–1.29, <em>I</em>^<em>2</em> = 36.2 %, <em>p</em> = 0.195 for heterogeneity) exhibited decreasing RFS, compared with those with OTTs of&lt;4 weeks. DFS and pCR rates were similar in&gt;8weeks vs &lt; 4 weeks and 4–8weeks vs &lt; 4 weeks.</div></div><div><h3>Conclusion</h3><div>Our systematic review and meta-analysis indicate that the optimal interval following NAC for breast cancer patients might be within four weeks, as delays exceeding eight weeks could be associated with poorer clinical outcomes. However, additional research is necessary to validate these preliminary findings.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104454"},"PeriodicalIF":5.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis","authors":"Rachel M. Layman ,&nbsp;Xianchen Liu ,&nbsp;Benjamin Li ,&nbsp;Lynn McRoy ,&nbsp;Adam Brufsky","doi":"10.1016/j.breast.2025.104448","DOIUrl":"10.1016/j.breast.2025.104448","url":null,"abstract":"<div><h3>Purpose</h3><div>To examine the associations of palbociclib dose modifications with clinical outcomes of patients with HR+/HER2− metastatic breast cancer (MBC) treated with first-line (1L) palbociclib + aromatase inhibitor (AI) in routine practice.</div></div><div><h3>Methods</h3><div>Using the Flatiron Health Analytic Database, we conducted a retrospective analysis of HR+/HER2− MBC patients who started 1L palbociclib + AI February 2015–March 2020. Kaplan−Meier analyses were used to estimate treatment duration, real-world progression-free survival (rwPFS), and overall survival (OS) by palbociclib dose adjustments (any change in palbociclib daily dose while on treatment) and dose reductions (starting dose &lt;125 mg/day or dose reduced while on treatment). Cox proportional hazard regression models were performed to compute unadjusted/adjusted hazard ratios (HRs).</div></div><div><h3>Results</h3><div>Of 1302 patients with documented starting dose, 524 (40.2 %) had palbociclib dose adjustments; 778 (59.8 %) had none. Median treatment duration was significantly longer in patients with dose adjustments versus those with none (27.4 vs 21.4 months; adjusted HR = 0.80 [95 % CI, 0.69–0.93]; <em>P</em> = 0.004). Patients with and without dose adjustments showed similar median rwPFS (20.5 vs 19.6 months; adjusted HR = 0.89 [95 % CI, 0.76–1.04]; <em>P</em> = 0.133). Median OS was significantly prolonged in patients with versus without dose adjustments (57.8 vs 51.4 months; adjusted HR = 0.73 [95 % CI, 0.59–0.89]; <em>P</em> = 0.002). Similar findings were observed in patients with and without dose reductions.</div></div><div><h3>Conclusions</h3><div>In this real-world study, rwPFS in HR+/HER2− MBC patients was maintained irrespective of dose adjustments. However, dose adjustments were associated with extended treatment duration and OS.</div></div><div><h3>Clinical trial registration</h3><div><span><span>NCT05361655</span><svg><path></path></svg></span> (<span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104448"},"PeriodicalIF":5.7,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143695963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of oncological outcomes of premenopausal with ovarian function suppression versus postmenopausal women in ER+/HER2- breast cancer","authors":"Min Jung Lee ,&nbsp;Ji-Jung Jung ,&nbsp;Jong-Ho Cheun ,&nbsp;Eunhye Kang ,&nbsp;Hong-Kyu Kim ,&nbsp;Han-Byoel Lee ,&nbsp;Hyeong-Gon Moon ,&nbsp;Wonshik Han","doi":"10.1016/j.breast.2025.104449","DOIUrl":"10.1016/j.breast.2025.104449","url":null,"abstract":"<div><h3>Background</h3><div>The Rx for positive node endocrine-responsive breast cancer trial highlighted that premenopausal (PRE) women who underwent chemotherapy exhibited superior survival rates compared to postmenopausal (POST) counterparts, but showed worse survival without chemotherapy. This raises the question whether application of ovarian function suppression (OFS) in PRE women aligns with their cancer biology, treatment response, and outcomes observed in POST women.</div></div><div><h3>Methods</h3><div>Data from the Seoul National University Hospital breast cancer cohort focusing on patients with stage pT1-3, pN0-1, estrogen receptor-positive (ER+), and HER2-negative breast cancer were analyzed. Survival outcomes, including invasive disease-free survival (iDFS) and distant relapse-free survival (DRFS), were compared between PRE women receiving OFS and POST women, with chemotherapy usage as a stratification factor. Propensity score matching was performed.</div></div><div><h3>Result</h3><div>We analyzed 3483 patients, comprising 2901 POST and 582 PRE women with OFS. In the cohort without chemotherapy, the 10-year iDFS rates were 90.3 % and 88.3 % (hazard ratio [HR], 1.32; p = 0.16), and 10-year DRFS rates were 94.3 % and 96.1 % (HR, 0.78; p = 0.41) for POST and PRE women with OFS, respectively. Among women treated with chemotherapy, 10-year iDFS rates were 83.0 % and 79.5 % (HR, 1.21; p = 0.37), and DRFS rates were 86.7 % and 85.7 % (HR, 1.14; p = 0.58) for POST and PRE women with OFS, respectively. These results remained consistent after PSM.</div></div><div><h3>Conclusion</h3><div>Oncological outcomes of PRE women receiving OFS were comparable to those of POST women with ER+ and HER2-early breast cancer, irrespective of chemotherapy administration.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104449"},"PeriodicalIF":5.7,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Metronomic chemotherapy using capecitabine and cyclophosphamide in metastatic breast cancer – efficacy, tolerability and quality of life results from the phase II METRO trial” [The Breast 78 (2004) 103795]","authors":"Karolina Larsson F ,&nbsp;Jamila Adra ,&nbsp;Leif Klint ,&nbsp;Barbro Linderholm","doi":"10.1016/j.breast.2025.104420","DOIUrl":"10.1016/j.breast.2025.104420","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 104420"},"PeriodicalIF":5.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Antibody-Drug conjugates in elderly patients with breast cancer” [The Breast 80 (2025) 104428]","authors":"Marta Bonotto ,&nbsp;Giulia De Pieri ,&nbsp;Rocco Esposto ,&nbsp;Ludovica Lay ,&nbsp;Silvia Buriolla ,&nbsp;Giuseppe Aprile ,&nbsp;Fabio Puglisi ,&nbsp;Alessandro Marco Minisini","doi":"10.1016/j.breast.2025.104440","DOIUrl":"10.1016/j.breast.2025.104440","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 104440"},"PeriodicalIF":5.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trajectories and predictors of financial toxicity in breast cancer patients: A multicenter longitudinal study in China","authors":"Yi Kuang ,&nbsp;Jiajia Qiu ,&nbsp;Ye Liu ,&nbsp;Sijin Guo ,&nbsp;Ting Chen ,&nbsp;Lichen Tang ,&nbsp;Winnie K.W. So ,&nbsp;Weijie Xing","doi":"10.1016/j.breast.2025.104441","DOIUrl":"10.1016/j.breast.2025.104441","url":null,"abstract":"<div><h3>Background</h3><div>Patients with breast cancer experience varying levels of financial toxicity (FT), but the factors contributing to sustained financial toxicity remain poorly understood.</div></div><div><h3>Methods</h3><div>This longitudinal study was conducted from November 2022 to March 2024 in China. Participants were recruited from four Tertiary Level A hospitals using convenient sampling. FT was assessed using the Comprehensive Score for Financial Toxicity (COST) at baseline (T1), 3 months (T2), 6 months (T3), and 12 months (T4) post-surgery. Growth Mixture Modeling was used to identify the different trajectories of the FT. Multivariable logistic regression were employed to explore the predictive factors with different trajectory categories.</div></div><div><h3>Results</h3><div>Among 378 participants (all women; median [SD] age, 48.9 [9.97] years), the COST score was lowest at T2. Three distinct FT trajectories were identified: 91 patients <strong>(24 %)</strong> in the \"Severe FT with Gradual Relief\" group (trajectory 1), 190 patients <strong>(50 %)</strong> in the \"Persistently Low-Level FT\" group (trajectory 2), and 97 patients <strong>(</strong>26 %<strong>)</strong> in the \"Moderate FT with Gradual Worsening\" group (trajectory 3). Using trajectory 2 as the reference, predictors for trajectory 1 included symptom burden, location, cancer stage, cost-related health literacy, resilience, and difficulty affording basic expenses. For trajectory 3, predictors included monthly household income, symptom burden, location, and cancer stage.</div></div><div><h3>Conclusions</h3><div>The FT experienced by breast cancer patients changes over time and follows distinct dynamic trajectories, influenced by multiple factors. In future clinical practice, early identification and intervention for high-risk FT groups should be prioritized.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104441"},"PeriodicalIF":5.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}